Aceso Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.30 M
- Company Age 9 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
About Aceso Pharma
Aceso Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 November 2015 (Nine years and three months 9 days old ). Its registered office is in Jind, Haryana, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹2.50 M.
Lalita Rani and Hitu serve as directors at the Company.
Company Details
-
Location
Jind, Haryana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999HR2015PTC057216
-
Company No.
057216
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Nov 2015
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Aceso Pharma?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Lalita Rani
![]() |
Director | 27-Mar-2019 | Current |
Hitu
![]() |
Director | 27-Mar-2019 | Current |
Financial Performance of Aceso Pharma.
Aceso Pharma Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
![Graph illustrating revenue growth over time](/Images/financial/revenue-growth.webp)
![Graph showing profit and loss trends over time](/Images/financial/profit-loss.webp)
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Aceso Pharma?
In 2017, Aceso Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
![Shareholding Indicator graph](/Images/tcc-login/Shareholding-Indiacator-1200.webp)
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.25 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
13 Sep 2023 | Others | ₹2.50 M | Open |
How Many Employees Work at Aceso Pharma?
Unlock and access historical data on people associated with Aceso Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
![Graph showing employee growth trends](/Images/tcc-login/Employee-Graph.webp)
Deals i
![Graph showing company valuation over time](/Images/tcc-login/Valuation-Graph-small.webp)
Gain comprehensive insights into the Deals and Valuation data of Aceso Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aceso Pharma's trajectory.
Rating
![Graph displaying rating trends over time](/Images/tcc-login/Rating-Graph-small.webp)
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
![Alert Indicator](/Images/tcc-login/Alert-Indicator-small.webp)
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.